| pubmed-article:15930985 | pubmed:abstractText | Despite the advent of the anti-TNF agent, infliximab, an important unmet medical need characterizes the medical treatment of inflammatory bowel diseases. This review aims to summarize recent progress in the field. | lld:pubmed |
